Abbott Says Sandoz Marketed Generic Nimbex Too Soon

Law360, New York (August 29, 2012, 2:19 PM EDT) -- An Abbott Laboratories unit sued Sandoz Inc. for $25 million in Illinois on Tuesday, claiming the rival drugmaker breached a settlement agreement reached during prior litigation by prematurely offering to sell a generic version of skeletal muscle relaxant Nimbex.

In a suit filed in Illinois federal court, AbbVie Inc. — which Abbott is scheduled to spin off as a stand-alone research-based pharmaceutical business later this year — accuses Sandoz of violating a June 2010 settlement agreement that resolved litigation over Sandoz’s bid to produce and sell...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.